Synthesis, characterization and pharmacological evaluation of certain sulfonamide containing heterocyclic motifs
More details
Hide details
Sri Krishnadevaraya University, Anantapur, A.P., India
IcfaiTech, Faculty of Science and Technology, ICFAI Foundation for Higher Education, Hyderabad, Telangana, India
Raghavendra Guru Prasad Aluru   

IcfaiTech, Faculty of Science and Technology, ICFAI Foundation for Higher Education, Hyderabad, Telangana, India. Tel.: +91 98496 94428.
Submission date: 2014-05-02
Acceptance date: 2014-07-17
Online publication date: 2014-08-15
Publication date: 2020-04-06
Pol. Ann. Med. 2014;21(2):75–81
Heterocycles containing nitrogen, oxygen and sulphur have diverse and exceptional therapeutical and industrial significance. Particularly sulfonamides containing pyrrolidine and thiophene moieties constitute an important class of drugs and display a variety of pharmacological activities.

To design, synthesize and characterize substituted sulfonamides and evaluate their in vitro antimicrobial activity and in silico HMG-CoA reductase inhibitory activity.

Material and methods:
The synthetic investigations have been well supported by elemental analysis data and standard modern spectroscopic techniques. The compounds were evaluated for their in vitro antimicrobial activity against Staphylococcus aureus NCCS 2079, Bacillus cereus NCCS 2106, Escherichia coli NCCS 2065, Aspergillus niger NCCS 1196 and Candida albicans NCCS 2106. In silico studies were done against 3VKK (PDB Id). Pharmacophore mapping studies were reported to analyze the important pharmacophore features and to predict the quantitative structure-activity relationship.

Results and discussion:
The antibacterial activity data revealed that compounds of 8 series were more active than the compounds of 7 series followed by compounds of series 6. In silico studies revealed that HMG-CoA reductase inhibitory activity of these drugs is of the order 'a > b > c > d > e > f'.

Antibacterial activity studies indicate that nitro and halo substituted sulfonamides of each series were more active than the other members. A detailed analysis from virtual screening data led to the conclusion that all these compounds are potential HMG-CoA reductase inhibitors and within each series, nitro substituted sulfonamide has demonstrated least drug score.

None declared.
Oh C-H, Cho H-W, Baek D, Cho J-H. Synthesis and antibacterial activity of 1b-methyl-2-(5-substituted thiazolo pyrrolidin-3-ylthio)carbapenem derivatives. Eur J Med Chem. 2002;37(9):743–754.
Qiu M, Chen Y, Cheng L, Chu Y, Song HY, Wu ZW. Pyrrolidine dithiocarbamate inhibits herpes simplex virus 1 and 2 replication and its activity may be mediated through dysregulation of the ubiquitin–proteasome system. J Virol. 2013;87(15):8675–8686.
Muhammad S, Amin B, Shah NA, et al. Antitumor antioxidant and antimicrobial studies of substituted pyridylguanidines. Molecules. 2013;18:10378–10396.
Kleanthous S, Borthwick AD, Brown D, et al. Structure and property based design of factor Xa inhibitors: pyrrolidin-2- ones with monoaryl P4 motifs. Bioorg Med Chem Lett. 2010;20(2):618–622.
Stefanie K, Matthias U, Wolfgang W, et al. Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals. US8329725 B2; 2012.
de Melo EB, Adriane da Silveira G, Ivone C. a- and bglucosidase inhibitors: chemical structure and biological activity. Tetrahedron. 2006;62(44):10277–10302.
Egbertson MS, Cook JJ, Bednar B, et al. Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alphasulfonamides are potent, long acting in vivo inhibitors of platelet aggregation. J Med Chem. 1999;42:2409–2421.
Alsaid MS, El-Gazzar MG, Ghorab MM. Anticancer activity of novel thiophenes containing a biological active diphenylsulfone, diazepin, piperidine, oxazepine, acryladehyde and sulfonamide moieties. Drug Res (Stuttg). 2013;63(5):263–269.
Alfred LW, John S, Yeh L-A, Matthew Robert R. Phenoxy thiophene sulfonamides and other compounds for use as inhibitors of bacterial glucuronidase. US20130345196 A1;2013.
Raju B, Chengde W, Rosario C, Ilya O, Fiona S, Chan MF. 2-Aryloxycarbonylthiophene-3-sulfonamides: highly potent and etA selective endothelin receptor antagonists. Bioorg Med Chem Lett. 1997;7(16):2093–2098.
Maggo S, Ashton JC. Effects of HMG-CoA reductase inhibitors on learning and memory in the guinea pig. Eur J Pharmacol. 2014;723:294–304.
Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet. 1997;32(5):403–425.
Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother. 1995;29(7–8):743–759.
Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Am J Geriatr Pharmacother. 2007;5(3):185–194.
Akira E. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 1992;33:1569–1582.
Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013.
Jones PH, Davidson MH, Stein EA, et al. Comparison of efficacy and safety of Rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses. Am J Cardiol. 2003;92:152–160.
Olsson AG, McTaggart F, Raza A, Rosuvastatin:. A highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev. 2002;20:303–328.
McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 2001;87(5A):28B–32B.
Wiegand I, Hilpert K, Hancock RE. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc. 2008;3:163–175.
Dirk K, Jürgen S, Christian R, et al. The coordination chemistry of cis-3,4-diaminopyrrolidine and related polyamines. Eur J Inorg Chem. 2001;10:2525–2542.
Hossein B, Seyed MS, Mina R, Mousa G. Synthesis of new disulfonamides from different substituted diamino pyridines. Eclet Quim. 2009;34:27–31.
Yildiz-Oren I, Ismail Y, Aki-Sener E, Nejat U. Synthesis and structure–activity relationships of new antimicrobial active multisubstituted benzazole derivatives. Eur J Med Chem. 2004;39:291–298.
Narayana Rao DV, Raghavendra Guru Prasad A, Spoorthy YN, Pariplavi M, Ravindranath LK. Synthesis, characterization and biological studies of substituted quinozoline-4-(3H)-one containing diazepine moiety. Ann Pharm Fr. 2014;72:51–58.
Sri Krishnanjaneyulu I, Saravanan G, Vamsi J, Supriya P, Udaya Bhavana J, Venkata Sunil Kumar M. Synthesis, characterization and antimicrobial activity of some novel benzimidazole derivatives. J Adv Pharm Technol Res. 2014;5:21–27.
Ekins S, Mestres J, Testa B. In silico pharmacology for drug discovery: applications to targets and beyond. Br J Pharm. 2007;152:21–37.
Shamsuzzaman. Ashraf M, Anis A, et al. Synthesis, evaluation and docking studies on steroidal pyrazolones as anticancer and antimicrobial agents. Med Chem Res. 2014;23:348–362.
Veber DF, Johnson SR, Cheng H-Y, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;4s:2615–2623.
Peter E, Bernhard R, Paul S. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem. 2000;43:3714–3717.
Clark DE. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena, prediction of intestinal absorption. J Pharm Sci. 1999;88:807–814.
Palm K, Luthman K, Ungell AL, Strandlund G, Artursson P. Correlation of drug absorption with molecular surface properties. J Pharm Sci. 1996;85:32–39.
van Breemen RB, Li Y. Caco-2 cell permeability assays to measure drug absorption. Expert Opin Drug Metab Toxicol. 2005;1:175–185.
Shityakov S, Neuhaus W, Dandekar T, Förster C. Analysing molecular polar surface descriptors to predict blood–brain barrier permeation. Int J Comput Biol Drug Des. 2013;6:146–156.
Palm K, Stenberg P, Luthman K, Artursson P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm Res. 1997;14:568–571.